These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28664816)

  • 1. CYP2C19*17 protects against metabolic complications of clozapine treatment.
    Piatkov I; Caetano D; Assur Y; Lau SL; Coelho M; Jones T; Nguyen T; Boyages S; McLean M
    World J Biol Psychiatry; 2017 Oct; 18(7):521-527. PubMed ID: 28664816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.
    Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA
    Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.
    Tan MSA; Honarparvar F; Falconer JR; Parekh HS; Pandey P; Siskind DJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):615-637. PubMed ID: 33410989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.
    Lu ML; Lane HY; Lin SK; Chen KP; Chang WH
    J Clin Psychiatry; 2004 Jun; 65(6):766-71. PubMed ID: 15291653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
    Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
    Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Determinants of Clozapine-Induced Metabolic Side Effects.
    Vasudev K; Choi YH; Norman R; Kim RB; Schwarz UI
    Can J Psychiatry; 2017 Feb; 62(2):138-149. PubMed ID: 27681143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.
    Tóth K; Csukly G; Sirok D; Belic A; Kiss Á; Háfra E; Déri M; Menus Á; Bitter I; Monostory K
    Int J Neuropsychopharmacol; 2017 Jul; 20(7):529-537. PubMed ID: 28340122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia.
    Guitton C; Kinowski JM; Abbar M; Chabrand P; Bressolle F
    J Clin Pharmacol; 1999 Jul; 39(7):721-8. PubMed ID: 10392327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine toxicity in a CYP2D6 poor metaboliser: Additive effects of haloperidol and valproate on clozapine metabolism.
    Reznik R; Chen RYY; Stanford P
    Australas Psychiatry; 2018 Dec; 26(6):608-611. PubMed ID: 29737183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia.
    Menus Á; Kiss Á; Tóth K; Sirok D; Déri M; Fekete F; Csukly G; Monostory K
    Sci Rep; 2020 Dec; 10(1):21283. PubMed ID: 33277605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients.
    Perry PJ; Miller DD; Arndt SV; Cadoret RJ
    Am J Psychiatry; 1991 Feb; 148(2):231-5. PubMed ID: 1670979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between serum clozapine concentrations and hematological parameters by a validated mass spectrometric method.
    Kamil Gharab KM; Onmaz DE; Abusoglu S; Aydin M; Sivrikaya A; Tok O; Abusoglu G; Unlu A
    J Pharm Biomed Anal; 2020 Feb; 180():113056. PubMed ID: 31887669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments.
    Arranz MJ; Gonzalez-Rodriguez A; Perez-Blanco J; Penadés R; Gutierrez B; Ibañez L; Arias B; Brunet M; Cervilla J; Salazar J; Catalan R
    Transl Psychiatry; 2019 Jul; 9(1):177. PubMed ID: 31346157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice.
    Turrion MC; Perez J; Bernardo M; Fernandez-Egea E
    Rev Psiquiatr Salud Ment (Engl Ed); 2020; 13(1):31-35. PubMed ID: 31122757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia.
    Xiang YQ; Zhang ZJ; Weng YZ; Zhai YM; Li WB; Cai ZJ; Tan QR; Wang CY
    Schizophr Res; 2006 Apr; 83(2-3):201-10. PubMed ID: 16524698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of clozapine and norclozapine in human serum using ultra-performance liquid chromatography- tandem mass spectrometry.
    Ming DS; Heathcote J
    J Anal Toxicol; 2009 May; 33(4):198-203. PubMed ID: 19470221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
    Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
    J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.
    Okhuijsen-Pfeifer C; van der Horst MZ; Bousman CA; Lin B; van Eijk KR; Ripke S; Ayhan Y; Babaoglu MO; Bak M; Alink W; van Beek H; Beld E; Bouhuis A; Edlinger M; Erdogan IM; Ertuğrul A; Yoca G; Everall IP; Görlitz T; ; Grootens KP; Gutwinski S; Hallikainen T; Jeger-Land E; de Koning M; Lähteenvuo M; Legge SE; Leucht S; Morgenroth C; Müderrisoğlu A; Narang A; Pantelis C; Pardiñas AF; Oviedo-Salcedo T; Schneider-Thoma J; Schreiter S; Repo-Tiihonen E; Tuppurainen H; Veereschild M; Veerman S; de Vos M; Wagner E; Cohen D; Bogers JPAM; Walters JTR; Yağcıoğlu AEA; Tiihonen J; Hasan A; Luykx JJ
    Transl Psychiatry; 2022 Apr; 12(1):145. PubMed ID: 35393395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics.
    Lane HY; Chang YC; Chang WH; Lin SK; Tseng YT; Jann MW
    J Clin Psychiatry; 1999 Jan; 60(1):36-40. PubMed ID: 10074876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain correlated with decrease in clozapine/N-desmethyl-clozapine ratio in a man with treatment-refractory schizophrenia.
    De Mel VN; Korman N; McArdle P; Siskind DJ
    Australas Psychiatry; 2018 Oct; 26(5):558-559. PubMed ID: 30269573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.